China puts 33 drugs on 'group buying' list
BEIJING - Chinese authorities have released a list of 33 drugs for centralized procurement in large quantities by public healthcare institutions amid their steady efforts to reform the drug procurement system and make medicines more affordable to patients.
Among the 33 drugs are those for treating major chronic diseases like high blood pressure and diabetes, as well as tumors and rare diseases, according to centralized procurement documents released by a national office in charge of the matter.
According to plans, the bid opening will be held on Jan 17 and medicines that go through the centralized procurement process will be available at lower prices to patients at public hospitals across the country starting in April.
The group buying will be carried out simultaneously nationwide.
- China's anti-graft efforts deepen in 2025, with 115 senior officials probed
- Norovirus infections sicken over 100 students in Guangdong school
- Snapshots of Chinese space station passing in front of sun
- China accelerates nuclear fusion engineering, targeting power generation demonstration by 2030
- Xinjiang leads China in cross-border rail traffic, central Asian connectivity in 2025
- Astronauts say training helped ensure safe return
